Evaluation of off-label rapamycin use to promote healthspan in 333 adults

Kaeberlein, T. L., Green, A. S., Haddad, G., Hudson, J., Isman, A., Nyquist, A., Rosen, B. S., Suh, Y., Zalzala, S., Zhang, X., Blagosklonny, M. V., An, J. Y., & Kaeberlein, M. (2023). Evaluation of off-label rapamycin use to promote healthspan in 333 adults. GeroScience, 45(5), 2757–2768. https://doi.org/10.1007/s11357-023-00818-1
Authors:
Tammi L Kaeberlein
Alan S Green
George Haddad
Johnny Hudson
Anar Isman
Andy Nyquist
Bradley S Rosen
Yousin Suh
Sajad Zalzala
Xingyu Zhang
Mikhail V Blagosklonny
Jonathan Y An
Matt Kaeberlein
Affiliated Authors:
Yousin Suh
Author Keywords:
aging
covid-19
healthspan
longevity
rapamune
sars-cov-2
side effects
sirolimus
Publication Type:
Article
Unique ID:
10.1007/s11357-023-00818-1
PMID:
Journal:
Publication Date:
Data Source:
PubMed

Record Created: